Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study.
antihistamines
chronic urticaria
ebastine
up-dosing
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
02
11
2021
accepted:
04
02
2022
pubmed:
19
2
2022
medline:
7
5
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
The second-generation antihistamines at licensed doses are first-line treatment in urticaria and up-dosing is recommended as second-line treatment. To assess the efficacy and safety of escalated doses of ebastine in patients with chronic urticaria (CU), we designed this study. Recruited patients with CU were treated with increasing doses of ebstine. Treatment started at the daily dose of 10 mg. The symptom is assessed weekly, and if there is no significant improvement, the dose is increased from 10 mg to 20 mg, and if still no significant improvement, up to 40 mg. Pruritus, number, diameter, duration and frequency of wheals, and adverse reactions were assessed. One hundred and forty (76.50%) patients achieved marked effect with ebastine 10 mg/day, 27 (14.75%) patients with ebastine 20 mg/day and 13 (7.10%) patients with ebastine 40 mg/day, while 3(1.64%) patients did not get marked effect. There was no significant difference of effect between factitious urticaria, CSU, cholinergic urticaria and CSU with factitious urticaria in different dose (all p > 0.05). Common adverse reactions of ebstine treatment, included dry mouth, somnolence, tiredness and headache, were mild or moderate. There was no significant difference between the degree score of dry mouth with different doses of ebastine, and the same to somnolence, tiredness and headache (all p > 0.05). Doses escalation of ebastine should be effective in treatment of factitious urticaria, CSU and cholinergic urticaria with poorly treated by standard of double doses. Increasing ebastine dose did not increase the incidence of adverse reactions.
Substances chimiques
Butyrophenones
0
Cholinergic Agents
0
Histamine H1 Antagonists
0
Piperidines
0
ebastine
TQD7Q784P1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15386Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270-1277.
Zuberbier T, Aberer W, Asero R. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-1414.
Okubo Y, Shigoka Y, Yamazaki M, Tsuboi R. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. J Dermatolog Treat. 2013;24:153-160.
Tanizaki H, Nakamizo S, Nakahigashi K, Miyachi Y, Kabashima K. A double dose of levocetirizine leads to better control of histamine-induced flare, wheal and itch in healthy donors. Pharmacology. 2013;92:71-74.
Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676-682.
Vincent J, Liminana R, Meredith PA, Reid JL. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol. 1988;26:497-502.
Hampel F Jr, Howland W 3rd, Van Bavel J, Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2004;14:56-63.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868-887.
Godse KV. Ebastine in chronic spontaneous urticaria in higher doses. Indian J Dermatol. 2011;56:597-598.
Zuberbier T, Munzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (Basel, Switzerland). 1996;193:324-327.
Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123:672-679.
Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175:1153-1165.
Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clinic Experiment Allergy J British Soc Allergy Clinic Immunol. 2002;32:489-498.
Campbell A, Michel FB, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs. 1996;52(Suppl 1):15-19.
Matsubara M, Tamura T, Ohmori K, Hasegawa K. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+−dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades. Biochem Pharmacol. 2005;69:433-449.
Shifei L, Qiquan C, Zhou Z, et al. Ebastine inhibites the degranulation and cytokine release of mast cells in vitro (in Chinese). Immunol J. 2018;34(3):220-224.
High-dose antihistamines for chronic spontaneous urticaria in adults. Drug Ther Bull. 2018;56:45-48.
Sastre J. Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience. J Investig Allergol Clin Immunol. 2019;30:156-168.
Timmerman H. Factors involved in the absence of sedative effects by the second-generation antihistamines. Allergy. 2000;55(60):5-10.
Chishty M, Reichel A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target. 2001;9:223-228.
Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003;31:312-318.
Tamai I, Kido Y, Yamashita J, Sai Y, Tsuji A. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine. J Drug Target. 2000;8:383-393.
Spitaler MM, Hammer A, Malli R, Graier WF. Functional analysis of histamine receptor subtypes involved in endothelium-mediated relaxation of the human uterine artery. Clin Exp Pharmacol Physiol. 2002;29:711-716.
Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203-2217.